Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/ß-catenin signaling

  • Authors: Bai-Cheng He, Jian-Li Gao, Xiaoji Luo, Jinyong Luo, Jikun Shen, Linyuan Wang, Qixin Zhou, Yi-Tao Wang, Hue H. Luu, Rex C. Haydon, Chong-Zhi Wang, Wei Du, Chun-Su Yuan, Tong-Chuan He, Bing-Qiang Zhang
  • View Affiliations

  • Published online on: Friday, December 3, 2010
  • Pages: 437-445
  • DOI: 10.3892/ijo.2010.858

Abstract

Colorectal cancer (CRC) is one of the most common and deadly malignancies in the world. Most CRCs are initiated by aberrant activation of the Wnt/ß-catenin signaling pathway. Despite the advances in its early diagnosis, optimized surgical approaches, and chemotherapies, the clinical management of advanced CRC requires effective adjuvant agents. Ginsenoside Rg3 is a single compound isolated from American ginseng (Panax quinquefolius L., Araliaceae) and Asian ginseng (Panax ginseng C. A. Meyer). We investigated the anticancer activity of Rg3 on colon cancer cells and its potential molecular mechanism behind Rg3's anticancer activity. We found that Rg3 inhibits cell proliferation and viability of cancer cells in vitro. This inhibitory effect of Rg3 is, at least in part, mediated by blocking nuclear translocation of the ß-catenin protein and hence inhibiting ß-catenin/Tcf transcriptional activity. Allelic deletion of the oncogenic ß-catenin in HCT116 cells renders the cells more sensitive to Rg3-induced growth inhibition. Using the xenograft tumor model of human colon cancer, we have demonstrated that Rg3 effectively inhibits the growth of tumors derived from the human colon cancer cell line HCT116. Histologic examination revealed that Rg3 inhibits cancer cell proliferation, decreases PNCA expression and diminishes nuclear staining intensity of ß-catenin. Taken together, our results strongly suggest that the anticancer activity of Rg3 may be in part caused by blocking the nuclear translocation of ß-catenin in colon cancer cells. This line of investigation may lead to the development of novel therapies in which Rg3 can be used as an effective adjuvant agent for the clinical management of colorectal cancers.
Journal Cover

February 2011
Volume 38 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

2012 Impact Factor: 2.773
Ranked #30/202 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
He, B., He, B., Gao, J., Gao, J., Luo, X., Luo, X., Luo, J., Luo, J., Shen, J., Shen, J., Wang, L., Wang, L., Zhou, Q., Zhou, Q., Wang, Y., Wang, Y., Luu, H., Luu, H., Haydon, R., Haydon, R., Wang, C., Wang, C., Du, W., Du, W., Yuan, C., Yuan, C., He, T., He, T., Zhang, B., & Zhang, B. (2011). Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/ß-catenin signaling. International Journal of Oncology, 38(2), 437-445.
MLA
He, He, Gao, Gao, Luo, Luo, Luo, Luo, Shen, Shen, Wang, Wang, Zhou, Zhou, Wang, Wang, Luu, Luu, Haydon, Haydon, Wang, Wang, Du, Du, Yuan, Yuan, He, He, Zhang, and Bing-Qiang Zhang. "Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/ß-catenin signaling." International Journal of Oncology International Journal of Oncology 38.2 (2011): 437-445.
Chicago
He, He, Gao, Gao, Luo, Luo, Luo, Luo, Shen, Shen, Wang, Wang, Zhou, Zhou, Wang, Wang, Luu, Luu, Haydon, Haydon, Wang, Wang, Du, Du, Yuan, Yuan, He, He, Zhang, and Bing-Qiang Zhang. "Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/ß-catenin signaling." International Journal of Oncology International Journal of Oncology 38 no. 2 (2011): 437-445.